A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-189 Tablets and ICP-189 Tablets in Combination with Anti-PD-1 Monoclonal Antibody in Patients with Advanced Solid Tumors.
Patients With Advanced Solid Tumors
DRUG: ICP-189
The incidence and severity of adverse event (AE) of ICP-189 assessed by NCI-CTCAE V5.0, To assess the safety and tolerability of ICP-189 in patients with advanced solid tumors., through study completion, an average of 2 years|Dose-Limiting Toxicities (DLTs), Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)., through study completion, an average of 2 years|Recommended Phase 2 Dose (RP2D) and/or maximum tolerated dose (MTD), To preliminarily determine the PR2D and the MTD of ICP-189 in patients with advanced solid tumors, through study completion, an average of 2 years
The maximum plasma concentration observed (Cmax), To evaluate the pharmacokinetic (PK) characteristics of ICP-189 in patients with solid tumors., through study completion, an average of 2 years|Time of maximum observed plasma concentration (Tmax), To evaluate the pharmacokinetic (PK) characteristics of ICP-189 in patients with solid tumors., through study completion, an average of 2 years|Elimination half-life (t1/2), To evaluate the pharmacokinetic (PK) characteristics of ICP-189 in patients with solid tumors., through study completion, an average of 2 years|Area under plasma concentration-time curve (AUC0-t and AUC0-âˆž), To evaluate the pharmacokinetic (PK) characteristics of ICP-189 in patients with solid tumors., through study completion, an average of 2 years|Apparent clearance (CL/F), To evaluate the pharmacokinetic (PK) characteristics of ICP-189 in patients with solid tumors., through study completion, an average of 2 years|Apparent volume of distribution (Vz/F), To evaluate the pharmacokinetic (PK) characteristics of ICP-189 in patients with solid tumors., through study completion, an average of 2 years|The objective response rate (ORR), To evaluate the preliminary anti-tumor activity of ICP-189., through study completion, an average of 2 years|Duration of response (DoR), To evaluate the preliminary anti-tumor activity of ICP-189., through study completion, an average of 2 years|Progression-free survival (PFS), To evaluate the preliminary anti-tumor activity of ICP-189., through study completion, an average of 2 years|Overall survival (OS), To evaluate the preliminary anti-tumor activity of ICP-189., through study completion, an average of 3.5 years
Pharmacodynamics, On-treatment versus baseline comparison of PD biomarkers e.g., phosphorylated form of extracellular signal-regulated kinase (pERK), dual specificity phosphatase 6 (DUSP6)., through study completion, an average of 2 years
A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-189 Tablets and ICP-189 Tablets in Combination with Anti-PD-1 Monoclonal Antibody in Patients with Advanced Solid Tumors.